It will be interesting to explore the potential use of USP19-CY as a prognostic biomarker in breast cancer treatment and its potential use as a molecular target either by redirecting splicing to yield USP19-ER or inhibiting its deubiquitinating activity with selective small molecules. This evidence concerns the gene USP19 and breast carcinoma.